Salute e Benessere
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight
FILSPARI (sparsentan) is a once-daily oral treatment that uniquely targets two key pathways, endothelin-1 and angiotensin II (also known as DEARA), in the progression of IgA nephropathy. It is the first approved non-immunosuppressive therapy for this condition. Endothelin-1 and angiotensin II contribute to kidney function decline by promoting inflammation and fibrosis, altering podocyte structure, causing podocyte loss, and increasing the permeability of the glomerular filtration barrier.
Additionally, both are vasoconstrictors that narrow blood vessels and raise pressure in the glomeruli. The drug received accelerated approval based on its ability to reduce proteinuria. Due to potential safety concerns, it is distributed under the FILSPARI Risk Evaluation and Mitigation Strategy (REMS) program. In Europe , it is marketed by CSL Vifor, and in Japan by Renalys Pharma. Results from the registration-enabling study are expected in the second half of 2025.
Learn more about FILSPARI projected market size for IgAN @
IgA nephropathy (IgAN) is an autoimmune disorder that disrupts kidney function by damaging the small blood vessels responsible for filtration. This damage is caused by an abnormal protein that harms the glomeruli, the kidneys' main filtering units. According to DelveInsight, there were approximately diagnosed prevalent cases of IgAN across the seven major markets in 2024, and this number is projected to grow at a through 2034. Current standard care involves the use of ACE inhibitors and angiotensin II receptor blockers (ARBs), primarily to manage associated symptoms like hypertension.
Currently, only a few drugs have been approved for IgAN treatment, including (Atrasentan) and (Iptacopan) by Novartis, (Sparsentan) by Travere Therapeutics, and (budesonide) by Asahi Kasei (Calliditas Therapeutics), among others. The treatment landscape is expected to undergo major changes between 2024 and 2034, driven by the introduction of innovative therapies. DelveInsight estimates the IgAN market across the seven key regions was valued at around in 2024 and is projected to grow at a strong CAGR of 30.5% from 2025 to 2034.
With targeted treatment options for IgAN only recently emerging and a pressing need for therapies that can delay progression to end-stage kidney disease (ESKD), significant advancements in this area are likely to profoundly reshape the market in the coming years.
Discover more about the IgAN market in detail @
Key companies advancing therapies for IgA nephropathy include (Zigakibart/FUB523), (Sefaxersen/RG6299/IONIS-FB-LRx), (ULTOMIRIS), (Atacicept), (Povetacicept), (Sibeprenlimab), (Felzartamab), (ARO-C3), (NM8074), (ADX-097), (WAL0921), and (TAK-079), among others.
In April 2025 , announced it had completed patient enrollment for its pivotal assessing atacicept in IgA nephropathy. The previous month, Otsuka Pharmaceutical submitted a Biologics License Application (BLA) to the FDA for sibeprenlimab, a monoclonal antibody aimed at inhibiting APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN.
Additionally, in , the European Commission granted to BION-1301 for primary IgAN, offering regulatory benefits to support its European development. Strengthening its renal pipeline, acquired in for up to , adding and other late-stage kidney-focused assets to its portfolio.
To know how does FILSPARI compare to other treatments for IgA nephropathy, visit @
Discover how FILSPARI is shaping the IgAN treatment landscape @
FILSPARI, developed by Travere Therapeutics, represents a significant advancement in the treatment of IgA Nephropathy, a rare and chronic autoimmune kidney disease. Approved under the FDA's accelerated approval program in early 2023, FILSPARI is the specifically targeting proteinuria in IgAN. It is a dual endothelin angiotensin receptor antagonist (DEARA), a novel mechanism that distinguishes it from . Its market entry has been notable for both its scientific innovation and potential to reshape the standard of care for IgAN, particularly in patients at high risk of progression to end-stage kidney disease (ESKD).
The market dynamics are influenced by multiple factors, including the , the
, and the in the space. Prior to FILSPARI's launch, treatment was largely supportive, focusing on blood pressure control and proteinuria reduction via ACE inhibitors or ARBs.
without the side effects associated with corticosteroids or immunosuppressants provides a compelling clinical and commercial value proposition.
Competition is evolving, with several companies advancing novel IgAN therapeutics. was approved ahead of FILSPARI for a similar indication, but works through a corticosteroid pathway. Other players are also advancing programs, suggesting the market could become more segmented based on patient profile and mechanism of action. FILSPARI's differentiated profile, especially its , positions it favorably among nephrologists and specialists, but maintaining this edge will require strong real-world evidence and ongoing clinical data.
From a market access and adoption standpoint, Travere has made early efforts in to accelerate uptake. However, broader adoption will depend on in delaying disease progression. As I through genetic and biomarker testing, the addressable patient population may expand, offering a significant growth opportunity for FILSPARI over the next 5–10 years.
Dive deeper to get more insight into FILSPARI's strengths & weaknesses relative to competitors @
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key IgAN companies such as among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgA nephropathy companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic kidney disease companies, including among others.
report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key chronic kidney disease companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/filspari-to-transform-kidney-disease-care-with-its-revolutionary-treatment-approach--delveinsight-302465527.html